Jerome B. Zeldis - Dec 2, 2024 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
Director
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Dec 2, 2024
Transactions value $
-$253,577
Form type
4
Date filed
12/4/2024, 05:20 PM
Previous filing
Nov 22, 2024
Next filing
Dec 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $612K +12K +82.76% $51.00 26.5K Dec 2, 2024 Direct F1
transaction PTCT Common Stock Sale -$453K -8.81K -33.26% $51.44 17.7K Dec 2, 2024 Direct F1, F2
transaction PTCT Common Stock Sale -$167K -3.19K -18.02% $52.42 14.5K Dec 2, 2024 Direct F1, F3
transaction PTCT Common Stock Options Exercise $370K +12K +82.76% $30.86 26.5K Dec 2, 2024 Direct F1
transaction PTCT Common Stock Sale -$288K -5.7K -21.51% $50.52 20.8K Dec 2, 2024 Direct F1, F4
transaction PTCT Common Stock Sale -$135K -2.63K -12.66% $51.43 18.2K Dec 2, 2024 Direct F1, F5
transaction PTCT Common Stock Sale -$192K -3.67K -20.18% $52.39 14.5K Dec 2, 2024 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise $0 -12K -100% $0.00 0 Dec 2, 2024 Common Stock 12K $51.00 Direct F7
transaction PTCT Stock Option (Right to Buy) Options Exercise $0 -12K -100% $0.00 0 Dec 2, 2024 Common Stock 12K $30.86 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on May 22, 2024
F2 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.10 to $52.09 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.10 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F4 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $50.00 to 50.995 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F5 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $51.00 to $51.86 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F6 This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $52.02 to $52.91 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F7 Currently exercisable.